San Francisco – November 7, 2024 – Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors. The transactions comprise a $125 million synthetic royalty with Royalty Pharma and $250 million of committed senior secured debt with investment funds managed by Pharmakon Advisors.
Lawyers Mischi a Marca, Shimeng Cheng and Addison Pierce lead the multidisciplinary team advising Geron, which included public companies partner Chadwick Mills, patent counseling and prosecution partner Jonathan Cousin, tax partner Xander Lee, and life sciences partner Jennifer Raab.
Cooley has previously advised Geron on various corporate and financing matters, including its $227.8 million follow-on offering in January 2023.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.